Introduction
The osteoclast and the osteoblast are two important mediators in the tightly regulated process of bone remodeling. The bone-forming osteoblasts are of mesenchymal origin while the multinucleated osteoclasts that are responsible for bone resorption, are derived from hematopoietic stem cells (HSCs) . The balance between production and destruction of bone can be disturbed, and this will result in either reduction (osteoporosis) or increase (osteopetrosis) of bone mass.
Osteopetrosis comprises a heterogeneous group of diseases with varying degree of osteoclast dysfunction and the most severe form is called infantile malignant osteopetrosis (IMO) 1 . Children with this rare disorder have normal or elevated numbers of osteoclasts, which are unable to resorb bone due to defects in the acidification of the subcellular space between the osteoclast and the bone surface [2] [3] [4] [5] .
Other cellular processes, like cytoskeletal organization and ruffled border membrane formation, have also been suggested to be disturbed 6, 7 .
The gene mutated in the majority of patients with IMO is called TCIRG1 (or ATP6I or OC116) 8 . The 2,7 kbp transcript codes for the α3 subunit of a proton pump used by the osteoclast to acidify the resorption area 9 . As a consequence of the lack of resorption, remodeling of bone is severely hampered, which results in dense and fragile bone 10 . This in turn causes bone marrow (BM) failure followed by anemia and hepatosplenomegaly 1, 11, 12 .
The only curative treatment for IMO is HSC transplantation, but this form of therapy is associated with high mortality, especially when HLA-identical donors are not available 13 . IMO is thus a candidate disease for development of gene therapy because of its fatal outcome early in life if treatment with HSC transplantation is not possible.
Since progression of the disease is rapid it is of importance to initiate the treatment as early as possible. Experience from gene therapy studies of other diseases with hematopoietic involvement, such as X-linked SCID and chronic granulomatous disease 14, 15 , show promising results. Gene therapy of IMO has so far not been tested in animal models or in patients. We have previously demonstrated that a mouse model of IMO, the oc/oc mouse, which has a 1500 bp deletion in the tcirg1 gene, can be treated with neonatal BM transplantation 16 . Here we show, both in vitro and in vivo, that the osteopetrotic phenotype in oc/oc mice can be reversed by transplantation of fetal liver derived oc/oc HSCs cells retrovirally transduced to express a non-mutated form of tcirg1. This represents the first report of osteoclast directed gene therapy and a first but significant step towards the development of gene therapy for osteopetrosis.
Materials and methods

Mice
Two pairs of (C57BL/6J x C3HheB/FeJ) F1 oc/+ mice (Ly5.2) were obtained from the Jackson Laboratory (Bar Harbour, ME) and maintained in the conventional animal facility at the Biomedical Centre, University of Lund. The mice had a mixed genotype in their HLA-locus (b/k), and were bred to obtain homozygotes (b/b). Transplanted oc/oc mice were fed mashed food due to lack of teeth eruption or dental abnormalities in the mice where teeth erupted. Because of abnormal wearing, teeth had to be kept short by cutting. All experiments were performed according to protocols approved by the local ethical committee. Oc/+ mice appeared normal and were phenotypically indistinguishable from wild type (WT) littermates.
Genotyping of mice
Mice were genotyped on the day of birth using DNA extracted from the tip of the tail.
P C R w a s p e r f o r m e d u s i n g t w o f o r w a r d p r i m e r s , F 1
(GATCATGGGCTCTATGGTTCCG), and one reverse primer, R1
(GCTCATTCCATGGGATGTGAATC). Forward primer F3 binds to the sequence deleted in tcirg1 in oc/oc mice. For identification of the genotypes the PCR products were loaded onto a 1 % agarose gel. Oc/oc mice were identified by a single band of 306 bp, oc/+ mice by one band of 306 bp and one band of 482 bp, and WT mice by a single band of 482 bp (Fig 1D) .
Retroviral vectors and producer cell lines
cDNA for the murine tcirg1 gene was amplified from a murine BM cDNA library (generated from a C57/BL6 mouse) using the forward primer This vector will be referred to as the tcirg1 vector ( Fig 1A) . A pSF91P vector expressing GFP preceded by IRES was used as a control vector ( Fig 1A) . Both vectors were transfected into Phoenix Ampho cells (Nolan lab, Stanford University, USA) and supernatants were harvested for transduction of the stable producer cell line GP+E86 (ecotrophic envelope) followed by selection of high titer clones. The titers were approximately 5x10 5 for the tcirg1 vector and 1x10 7 for the control vector.
Northern blot on 3T3 cells transduced with the tcirg1 vector
3T3 cells were transduced with vector containing medium (VCM) from the tcirg1 stable vector producing cell line and total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA). Untransduced 3T3 cells were used as control cells.
Briefly, RNA was separated on an agarose gel and blotted to a membrane. For the hybridization, a probe produced by digestion of the tcirg1 vector with FspI (1995 bp band) was used.
Harvest and enrichment of fetal liver hematopoietic cells
On embryonic day 14.5 pregnant mice were sacrificed by CO 2 poisoning, and embryos were removed. Fetal livers (FLs) were dissected out and put into PBS (Invitrogen) supplemented with 2 % FCS (Invitrogen). Single-cell suspensions were prepared by drawing liver cells through a 23-gauge needle followed by filtering through a 50-µm cell strainer. Individual FLs were genotyped by lysing a cell sample and running the PCR reaction described above for the genotyping of mice. Culture media were replaced every 3 days. At the end of the culture period, cells were fixed in PBS buffered 4 % formaldehyde and stained for tartrate resistent acid phosphatase (TRACP) activity using the leukocyte acid phosphatase kit (Sigma).
Nuclei were stained with diamidino-2phenylindole dihydrochloride (DAPI).
In vitro bone resorption
For bone resorption assays, the bone slices were cleaned from the cells by incubating For provirus copy number determination DNA was isolated from transduced oc/oc fetal liver cells and quantitative PCR was performed as described above using the following primers: Tcirg1 forward primer GATCATGGGCTCTATGTTCCG and reverse primer GTCTCTGAACTCCACGAG and actin forward primer CAC CACAGCTGAGAGGGAAA and reverse primer GTCAGGCAGCTCATA GCTCTT.
Analysis was done with LightCycler Software version 5.32. Tcirg1 PCR values were normalized to the corresponding hprt and actin values.
X-ray analysis
Prior to X-ray analysis transplanted or control mice were sacrificed with CO 2 . The Xray examination was performed at the University Hospital in Lund.
Histology
Femurs were dissected from the mice and following fixation in PBS containing 4 % formaldehyde, the bone was put in Parengy decalcification solution (0.15 % chromethrioxid, 4.3 % nitric acid and 30 % ethanol) (Bie & Berntsen A-S, Copenhagen, Denmark) for 48 hours. After paraffin embedding, the femurs were subsequently sectioned and stained with Erlish eosin for microscopic examination.
Statistical analysis
Mean values and standard deviations (SD) were computed in Excel (Microsoft, Redmond, WA). Student's t-test was used for comparisons. Levels of significant difference shown as * (p<0.05) and ** (p<0.005).
Results
Ter119 depleted fetal liver HSCs can be efficiently transduced with retroviral vectors.
We have previously shown that oc/oc mice can be cured by neonatal transplantation of normal BM cells 16 vector, 42-85 % ( Table 2 ). The provirus copy number in transduced cells was determined by quantitative PCR and found to be in the range of 3.5-5.5 copies per GFP positive cell when the transduction efficiency was 81% (SD 3%, n=6).
Transplantation of normal fetal liver cells transduced with a GFP vector cures oc/oc mice from osteopetrosis and gives rise to long-term engraftment.
To determine if FL HSCs have the same ability to cure oc/oc mice as BM cells, Ter119 depleted WT FL cells transduced with the GFP control vector were transplanted into sub-lethally irradiated 1-day-old oc/oc mice (n=3, were transduced with the tcirg1 vector (Fig 1) . Transduced cells were transplanted i.p.
into 1-day-old mice irradiated with 400 cGy (Fig 1) . Eight out of 15 transplanted mice survived past the normal short life-span of oc/oc mice and these are shown in Table 2 Reconstitution in oc/oc+tcirg1 mice was analyzed by flow cytometry of PB at different time-points after transplantation. All surviving mice had sustained reconstitution of GFP + cells as shown in Table 2 , and also exhibited multi-lineage GFP-marking (Fig 2 A) , suggesting transduction of hematopoietic stem or early progenitor cells. It has previously been shown that oc/oc mice have a block in B lymphopoiesis, probably due to reduced production of IL-7 in the BM microenvironment, and as a result a reduced number of B-cells in PB 19, 20 . In order investigate if the peripheral B-cell deficiency was corrected, multi-lineage analysis of PB was performed at 8 and 12-18 weeks post transplant (Fig 2 A) . We previously showed that PB lineage distribution was normalized in oc/oc mice transplanted with normal BM cells 16 . In the present study we can see a significant rise in the mature B220 + B-cell population in oc/oc+tcirg1 mice 12-18 weeks post transplant as compared to untreated oc/oc mice and the level is not significantly different from WT controls (Fig 2 B) .
Bone marrow cells harvested from transplanted oc/oc+tcirg1 mice form bone resorbing osteoclasts in vitro.
To investigate if transduced oc/oc FL cells can differentiate into bone resorbing osteoclasts we harvested BM cells from oc/oc+tcirg1 mice and cultured these in vitro with M-CSF and RANKL. Both green fluorescent and non-fluorescent multinucleated cells formed from oc/oc+tcirg1 BM after 6 days of culture, whereas only nonfluorescent cells formed from WT BM (Fig 3 A) . BM from oc/oc+tcirg1 mice was also sorted into populations of GFP + and GFP -cells before in vitro culture. The number of osteoclasts (TRACP positive cells with ≥ 3 nuclei per cell) that formed was similar between genotypes (WT and oc/oc+tcirg1) and the two sorted cell populations from the oc/oc+tcirg1 mice (Fig 3 B) . The distribution of the various categories of multinucleated cells (3-5, 6-10 and more than 10 nuclei per cell) was similar between these four groups (data not shown).
We further assessed the in vitro bone resorbing activity of osteoclasts derived from BM cells from WT mice and oc/oc+tcirg1 mice after 6 and 14 days of culture on bovine bone slices. After 6 days, only WT cells exhibited signs of bone resorption (Fig 4) , whereas after 14 days of culture also the oc/oc+tcirg1 cells were able to 
The level of expression of tcirg1 in oc/oc+tcirg1 osteoclasts is reduced as compared to WT cells.
Quantitative RT-PCR was performed on cDNA from freshly harvested BM cells (0 days) and in vitro differentiated osteoclasts (6 days) from WT and oc/oc+tcirg1 mice to determine the level of tcirg1 expression (Fig 5) . In addition, the vector producing cell lines GP+E86 (control vector) and GP+E86 tcirg1 (tcirg1 vector) were used as a comparison of vector expression.
In WT cells, tcirg1 was up-regulated as the cells differentiated towards osteoclast like cells, which is in line with previous observations 21 . In freshly harvested BM cells from oc/oc+tcirg1 mice expression from the LTR-driven vector insert was high.
However, during the in vitro differentiation towards the osteoclast lineage, the expression of tcirg1 from the vector decreased. Tcirg1 expression could not be detected in the GFP negative cells sorted from oc/oc+tcirg1 mice (data not shown).
X-ray examination and histology show formation of bone marrow space
In order to examine the skeletal phenotype mice were analyzed with X-ray and histology. The first analysis was performed 8 weeks post-transplantation. At this time partial remodelling of the bone was observed as detected by X-ray analysis and histology (Fig 6) . Analysis 18 weeks after transplantation showed that the bone structure and bone marrow was almost normalized (Fig 6) . Transduction of oc/oc
HSCs with the tcirg1 vector can thus restore the bone resorbing activity in vivo to a sufficient degree to reverse the osteopetrotic process in oc/oc mice, even though bone resorption in vitro was limited.
Discussion
The field of osteoclast biology has developed rapidly during recent years, in part due to knowledge gained from genetic and molecular examination of several mouse models of osteopetrosis, both spontaneous and induced 22 . This condition involves an increase in bone mass, which leads to a number of symptoms of variable severity depending on the mechanism underlying the disease. Osteopetrosis may be caused by defects in osteoclast development or by a reduction in osteoclast function. In terms of correlation between the osteopetrotic mouse models and human forms of these diseases, only mutations affecting osteoclast function have so far been identified as having human counterparts 22, 23 . The most severe form of osteopetrosis in humans is IMO. Mutations in three genes, giving rise to three separate single gene disorders all recessive in trait, have so far been shown to cause IMO [2] [3] [4] 6 . The most common gene involved is called TCIRG1, the product of which functions as a subunit of a proton pump used by the osteoclast to acidify the space between the cell and underlying bone. The homologue tcirg1 is spontaneously mutated in the oc/oc mouse leading to progressive osteopetrosis and death 3-4 weeks after birth. A previous report concluded that the oc/oc mouse was resistant to treatment with BM transplantation 24 .
This observation was somewhat puzzling considering that osteoclasts develop from HSCs and that the human form of disease can be treated with HSC transplantation.
However, recently, we were able to show that the oc/oc mouse is indeed curable by neonatal transplantation of BM cells if these, in contrasts to the previous study, are enriched for H2-matched stem cells 16 .
HSCs have been one of the primary targets for gene therapy since these are a readily accessible cell source that can be harvested from patients and re-infused after ex vivo manipulation. However, despite the fact that the osteoclast is a part of the hematopoietic system, no gene therapy attempts targeting osteoclasts or their precursors have, to our knowledge, been performed previously.
Here we demonstrate for the first time that osteopetrosis can be reversed by transplantation of gene modified HSCs leading to long-time survival of oc/oc mice suffering from an otherwise rapidly and lethally progressive form of this disease.
Eight out of 15 treated oc/oc animals survived past the normal lifespan of oc/oc mice and exhibited signs of osteoclast activity both in vivo and in vitro. In our previously However, secondary transplants would have to be performed to formally prove stem cell gene transfer.
The overall response rate in the present study (8/15 ) is approximately the same as seen in a similar murine ex vivo gene therapy study of . In the present study we choose to deliver the cells by i.p. injection as this resulted in a high survival rate in our previous transplantation study 16 . It is possible, though, that iv injection of gene modified cells would improve the results shown here and maybe also lower the cell dose required.
When osteoclasts were generated and cultured in vitro from BM of oc/oc+tcirg1 mice, there was no sign of bone resorption during a standard culture period of 6 days.
Increasing the culture period from 6 to 14 days resulted in bone resorption, however The only existing curative treatment for patients with IMO is HSC transplantation, which is associated with high mortality, especially if an HLA-identical sibling donor is not available 13 . This in combination with the rapid progression of the disease makes gene therapy an attractive option. A potential problem for gene therapy is to obtain a sufficient amount of BM cells for in vitro transduction since affected children have reduced BM cavities due to reduction of the marrow space. However, as IMO patients have increased levels of stem and progenitor cells circulating in the PB, one option would be to harvest CD34 + cells for in vitro transduction from the PB, possibly without need for any prior mobilization regimen to be given 30 . However, it should be stated that a fairly high number of gene corrected cells was transplanted to each recipient in the current study and the amount of cells needed to correct the disease in humans remains to be investigated.
Just as mice transplanted with normal BM 16 , oc/oc+tcirg1 mice remain growth retarded. Growth retardation is likely to be sustained also in patients after gene therapy since the experience from HSC transplantation show sustained growth impairment even in patients transplanted early (before 3 months of age) 13 . Only transplantation in utero seems to be able to result in normal size of oc/oc mice 31 .
However, in the clinical setting, this form of therapy will be an option only in families with a known history of the disease when a prenatal diagnosis is made and it is also technically more complicated to perform.
In conclusion we have demonstrated that the osteopetrosis characteristic for oc/oc Note that bone marrow volume increases at the expense of bone volume in oc/oc+tcirg1 compared to untreated oc/oc mouse. Olympus BX45 microscope and Nikon Prixera PRO 150 ES was used for the histology images. Figure 1 
